Atossa Therapeutics
ATOS
12 hedge funds and large institutions have $305K invested in Atossa Therapeutics in 2017 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
20% more funds holding
Funds holding: 10 → 12 (+2)
7% more capital invested
Capital invested by funds: $285K → $305K (+$20K)
0.03% more ownership
Funds ownership: 0.03% → 0.06% (+0.03%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$97.8K |
| 2 |
Renaissance Technologies
New York
|
+$66.6K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$40.3K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$26.3K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$16.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$511 |
ATOS Hedge Fund Activity: Q1 2017 in Review
12 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q1 2017, worth a combined $305K — up 7% from $285K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ATOS positions and 2 closed out — a net gain of 4 holders — while 4 added to existing stakes and 0 trimmed.
The largest buyer was Hudson Bay Capital Management, opening a new position worth an estimated $97.8K. The largest seller was Deutsche Bank, exiting entirely with an estimated $511 sold.
- 12 institutional investors held Atossa Therapeutics (ATOS) as of Q1 2017, up from 10 in Q4 2016.
- Funds reported $305K of Atossa Therapeutics stock for Q1 2017, up 7% quarter-over-quarter.
- 6 funds opened new Atossa Therapeutics positions in Q1 2017 and 2 closed out, a net change of +4 holders.
- The largest Atossa Therapeutics buyer in Q1 2017 was Hudson Bay Capital Management, an estimated $97.8K added.
- The largest Atossa Therapeutics seller in Q1 2017 was Deutsche Bank, an estimated $511 sold.
Based on aggregated 13F filings for Q1 2017.